Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy for ocular toxoplasmosis

A Rothova1, C Meenken, H J Buitenhuis

  • 1Department of Ophthalmology, Academic Medical Centre, Amsterdam, The Netherlands.

American Journal of Ophthalmology
|April 15, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of conjunctival, episcleral and scleral thickness in healthy individuals using anterior segment optical coherence tomography.

Acta ophthalmologica·2023
Same author

Subconjunctival Rituximab Administration for the Treatment of Scleritis.

Ocular immunology and inflammation·2022
Same author

Clinical Relevance of Autoantibodies and Inflammatory Parameters in Non-infectious Scleritis.

Ocular immunology and inflammation·2021
Same author

Recurrences of Scleritis after Ocular Surgery.

Ocular immunology and inflammation·2021
Same author

Current insights in the pathogenesis of scleritis.

Experimental eye research·2020
Same author

Successful Tocilizumab Treatment for Scleritis.

Ocular immunology and inflammation·2019
Same journal

Performance of the ISOLD Score (Interleukin Score for IntraOcular Lymphoma Diagnosis) in the Diagnosis of Vitreoretinal Lymphoma in Clinical Practice.

American journal of ophthalmology·2026
Same journal

Reply to Comment on Visual Field Progression in Glaucoma Patients with Delayed Follow-Up.

American journal of ophthalmology·2026
Same journal

Comment on: "Safety and efficiency reducing retinopathy of prematurity guideline sensitivity: an external validation using a large US-based dataset".

American journal of ophthalmology·2026
Same journal

Reply to Comment on "Clinicopathological and Imaging Distinction Between Ocular Adnexal MALT Lymphoma and IgG4-Related Ophthalmic Disease".

American journal of ophthalmology·2026
Same journal

Comment on: Visual Field Progression in Glaucoma Patients With Delayed Follow-Up.

American journal of ophthalmology·2026
Same journal

Corneal sensitivity changes and nerve plexus abnormalities in noninfectious anterior uveitis.

American journal of ophthalmology·2026
See all related articles

Current ocular toxoplasmosis treatments show no significant difference in inflammatory activity duration. Retinal lesion size, not treatment, is the key predictor, though pyrimethamine may reduce lesion size but increases side effects.

Area of Science:

  • Ophthalmology
  • Infectious Diseases
  • Parasitology

Background:

  • Ocular toxoplasmosis, a parasitic infection, can cause significant visual impairment.
  • Current therapeutic strategies involve various triple-drug combinations, but their comparative efficacy remains under investigation.

Purpose of the Study:

  • To evaluate the efficacy of three different triple-drug regimens for ocular toxoplasmosis.
  • To identify factors influencing the duration of inflammatory activity and recurrence rates.

Main Methods:

  • A prospective multicenter study involving 149 patients with ocular toxoplasmosis.
  • Comparison of three treatment groups: pyrimethamine, sulfadiazine, and corticosteroids; clindamycin, sulfadiazine, and corticosteroids; and trimethoprim, sulfamethoxazole, and corticosteroids.

Related Experiment Videos

  • Exclusion of patients with peripheral retinal lesions from systemic treatment.

    • Main Results:

    • No significant difference in the duration of inflammatory activity was observed between treated and untreated patients (P = .5).
    • Retinal lesion size was the most significant predictor of inflammatory activity duration (P < .001).
    • Pyrimethamine treatment showed a higher reduction in lesion size (49%) compared to untreated patients (20%) (P < .01), but also had the most frequent side effects (26%).
    • The overall recurrence rate after three years was 49%, with no difference between treated and untreated groups (P = .6).

    Conclusions:

    • Current therapeutic strategies for ocular toxoplasmosis do not significantly alter the duration of inflammatory activity.
    • Retinal lesion size is a critical factor in disease duration, independent of treatment.
    • While pyrimethamine may reduce lesion size, its associated side effects warrant consideration. Recurrence rates are high and unaffected by current treatments.